Tech Company Financing Transactions

Thesan Pharmaceuticals Funding Round

On 2/25/2014, Thesan Pharmaceuticals announced $49 million in Series B funding from Novo Ventures, Lundbeckfond Ventures and Novartis Venture Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

5864 Owens Ave. 200
Carlsbad, CA 92008
USA

Phone

Undisclosed

Website

www.thesanpharma.com

Email Address

[email protected]

Overview

Thesan Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin. Thesan is focused on the discovery and development of New Chemical Entities that have the potential to provide significantly improved treatment options to patients.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Bernard King

        

Chief Financial Officer

Leslie Schulze

        

Chief Medical Officer

Howard Welgus

        

Executive Vice President

George Mooney

        

VP - Product Management

Jay Birnbaum

        

VP - Regulatory Affairs

Charlotte Merritt

        

Browse more venture capital transactions:

Prev: 2/25/2014: TPI Composites venture capital transaction
Next: 2/25/2014: Saisei venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary